Table 2 The components involved for each type of signaling with available inhibitors and their current state in clinical trials.
From: Mechanisms and therapeutic potential of the hedgehog signaling pathway in cancer
Signal path element | Inhibitor | Mode of action | Clinical trial status | Reference |
---|---|---|---|---|
Smo inhibitors | Vismodegib | Keeped the transcription factors GLI1/2 in an inactive state. | Phase I and II trials | |
sonidegib | Blocked the abnormal activation of the HH signaling pathway. | Phase I and II trials | [145] | |
Cyclopamine | Binded to the seven-helix receptor of Smo protein. | Preclinical | [149] | |
Inoscavin A | Reduced the expression levels of key proteins in the Hh signaling pathway, such as Shh, Ptch1, Smo and Gli1. | Preclinical | [151] | |
Gli inhibitors | Garcinone C | Inhibited AKT phosphorylation and induced G0/G1 arrest. | Preclinical | [152] |
GANT61 | Its hydrolysate, GANT61-D, binded to a specific region of Gli1 protein. | Preclinical | [155] | |
HH78 | competitively binded to SMO and suppressed GLI transcriptional activity. | Preclinical | [156] | |
ATO | Directly inhibited the transcriptional activity of GLI1 protein and blocked HH/GLI signaling pathway | Phase I, II and III trials | [146] | |
PI4KB inhibitors | Pipinib | Selective inhibition of PI4KB reduced PI4P levels and prevented HH-mediated ciliary localization of Smo protein. | Preclinical | [154] |